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Background. The therapeutic management of psoriasis includes conventional treatments as well as the new generation of highly
effective TNF-𝛼 inhibitors. However, psoriasis has proven to be a complex therapeutic challenge and treatment failures are not
uncommon. Thus, laboratory biomarkers of disease progression/therapeutic efficacy may greatly help in the clinical management
of psoriasis. Aims. To identify laboratory biomarkers for clinical management and therapeutic monitoring of psoriasis. Methods.
An observational study performed on 59 patients, presenting moderate to severe psoriasis, undergoing treatment with anti-TNF-𝛼
agents (etanercept, adalimumab, and infliximab). Soluble and cellular immune/inflammatory parameters were assessed at baseline
and after 12 and 24 weeks of treatment. Results. Clinical efficacy was achieved in 88% of the subjects at 12 weeks, reaching 90% after
24 weeks. IL-6 and IL-22, which were elevated at baseline, were significantly reduced, in association with a significant decrease of
CLA+ T cells and an increase of Treg lymphocytes. T, B, and NK cell subsets and T cell response to recall antigens did not show
any evidence of immune suppression. Conclusions. Immune/inflammatory parameters including IL-6 and IL-22, CLA+ T cells, and
Treg lymphocytes may prove to be valuable laboratory tools for the clinical and therapeutic monitoring of psoriasis.
1. Introduction
Psoriasis is an inflammatory and hyperproliferative disease
of the skin and joints of unknown etiology, however char-
acterized by a multifactorial genetic basis [1, 2]. Psoriasis
has a strong genetic component; there is a positive family
history in a high percentage of affected children [3, 4]
and candidate genes linked to psoriasis are associated with
the acquired or innate arms of the immune system [5–7].
Psoriasis is considered an autoimmune disorder mediated by
T cells which, after priming by bacterial antigens, migrate to
the skin where they are activated by self-antigens expressed
by epithelia [5, 8] and the key participation of dendritic
cells that appear also increased in the skin [9]. Soluble
biologic mediators produced by activated T cells or by
dendritic cells, such as interferon 𝛾 (IFN-𝛾), tumor necrosis
factor-𝛼 (TNF-𝛼), IL-17, and IL-22, can induce inflammatory
molecules and angiogenic factors in keratinocyte and alter
their differentiation pathway [5, 10]. These events lead to the
cutaneous expression of the disease which consists in large
erythematous desquamative plaques. However, psoriasis is
frequently associatedwith the development of arthritis (PsA),
due to focal bone erosion and repair processes consequent
to inflammatory involvement of peripheral or axial joints
[11, 12]. A key role in development of psoriatic lesions
appears to be due to the expression of homing receptors
by activated T cells, facilitating their migration to the skin
[13]. Among them, the cutaneous lymphocyte-associated
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antigen (CLA), an epitope generated by fucosyltransferase-
VII mediated modification of P-selectin glycoprotein ligand-
1, which binds to E-selectin on vascular endothelium in the
skin [14], might be particularly relevant for the pathogenesis
of the disease, since evolving psoriatic skin lesions have
been described to be enriched with CLA+ T cells when
compared with stable lesions and distant uninvolved skin
[15]. A strong positive correlation has been found between
the frequency of CLA+ T cells in the blood of untreated
psoriasis patients and their disease severity [16]. As a result,
a complex cytokine network appears activated in psoriatic
lesions.This includes elevated levels of IFN-𝛾, TNF-𝛼, several
interleukins (IL-1, IL-2, IL-6, IL-8, IL-12 (p40 subunit), IL-
17, and IL-19), and multiple chemokines [6, 7]. Among the
inflammatory molecules influencing the keratinocytes, TNF-
𝛼 appears critical in sustaining most of the clinical manifes-
tations of psoriasis, at both the joint and skin localizations.
TNF-𝛼 is secreted by effector cells belonging to either the
innate or the adaptive immune system and is capable of
amplifying the response of both systems with pleiotropic
modalities [17]. This notion is reinforced by the results of
clinical trials based on the administration of anti-TNF-𝛼
therapy in patients with psoriatic arthritis [18–21]. A further
link between altered immunologic circuitries, lymphocytes
infiltration, and epidermal hyperplasia has been provided
by recent studies which show that T cells expressing IL-17
may play a major role in psoriasis [22, 23]. This pathological
immune circuitry appears driven by interleukin-23 [24].
In mice, injection of IL-23 leads to epidermal hyperplasia
mediated by IL-22 which, in turn, is produced by IL-17-
expressing T cells [25]. A similar scenario is suggested by
study in humans [26, 27]. On the other hand, an impairment
of regulatory T lymphocytes (Treg) may play a pivotal role in
the pathogenesis of the disease. In fact, the balance between
regulatory and effector functions is important for maintain-
ing efficient immune responses, while avoiding autoimmu-
nity. Indeed, the hyperproliferation of pathogenic effector T
cells in psoriasis has been associated with either a reduction
or a functional impairment of blood and tissue Treg cells
[28, 29].
The therapeutic approach to psoriatic patients is based
on two major categories of drugs, namely, the conventional
immunosuppressive drugs (i.e., methotrexate cyclosporine)
or acitretin and the last generation biological agents. In
addition to TNF-𝛼 antagonists such as infliximab (a chimeric
monoclonal antibody composed of a human IgG1 con-
stant region and a murine variable region), etanercept (a
soluble TNFR, made of two extracellular domains of the
human TNFR2 fused to the Fc fragment of human IgG1),
or adalimumab (a human monoclonal antibody), a new
drug (ustekinumab), an antibody targeting the common p40
subunit of IL-23 and IL-12, has been introduced in the
therapeutic management of psoriasis [30, 31]. The advent
of biological drugs has greatly improved the therapeutic
management of psoriasis [32]. However, psoriasis has proven
to be a difficult therapeutic challenge and treatment failures,
even with newer biologic therapies, are not uncommon [33].
Thus, the identification of laboratory parameters for use as
surrogate biomarkers for disease assessment and monitoring
Table 1: Clinical characteristics of patients and treatments.
Therapy
(patients) 𝑇
PASI 50
patients
%
PASI 75
patients
%
PASI 90
patients
%
All treatments
(51)
12 weeks 12 3 31
23.5% 5.9% 60.8%
24 weeks 4 6 39
0.7% 10% 76%
Etanercept
(27)
12 weeks 12 2 9
44.4% 7.4% 33.3%
24 weeks 4 5 17
14.8% 18.5% 62.1%
Adalimumab
(11)
12 weeks 0 1 10
0.0% 9.0% 90.1%
24 weeks 0 1 10
0% 10% 90%
Infliximab
(13)
12 weeks 0 0 12
0.0% 0.0% 92.3%
24 weeks 0 0 12
0.0% 0.0% 92.3%
of therapeutic efficacy, including information about long-
term immunological safety, should represent a valuable tool
to assist in the clinical and therapeutic management of the
disease. To this aim, we have evaluated different immuno-
logical parameters in patients affected by moderate to severe
psoriasis undergoing systemic treatment with biologic drugs
in a controlled clinical study, aimed at assessing the efficacy of
different treatment, in order to identify immunologic profiles
useful for disease assessment and therapeutic management of
patients.
2. Materials and Methods
2.1. Study Design. An open prospective observational study
(n. RS0209, Ethical Committee Approval n. 64/109), designed
to assess the efficacy of therapeutic regimens based on
the administration of anti-TNF-𝛼 drugs (etanercept, adal-
imumab, and infliximab), was performed in two clinical
centers (Tor Vergata University of Rome and the San Gal-
licano Dermatology Institute) in Rome, Italy, after approval
by the institutional ethical committees and in accordance
with the Declaration of Helsinki. A further objective of the
study, which included patients affected by moderate to severe
psoriasis, was to explore different immunological parameters
to assess their potential for use in the clinical assessment and
therapeutic management of patients.
2.2. Study Population. A total of 59 patients affected by
moderate to severe active plaque-type psoriasis have been
enrolled in the study. The population included 19 female
and 40 male patients, aged 46.3 ± 12.3 years. The clinical
characteristics are described in Table 1. They did not receive
any systemic therapy for at least one month and topical
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Table 2: Clinical efficacy of TNF-𝛼 inhibitors on skin involvement.
Therapy Patients Skin involvement Skin and joint involvement Joint involvement
All patients 59 32 19 8
∗PASI = 12 (8.5–39.6) PASI = 10.35 (1.8–34.2)
Etanercept 29 17 10 2
PASI = 12 (8.5–26) PASI = 12 (1.8–15.3)
Adalimumab 15 7 4 4
PASI = 12.2 (10.3–33) PASI = 15 (13–15)
Infliximab 15 8 5 2
PASI = 12 (10–39.6) PASI = 5.8 (4–34.2)
∗Median and range.
therapy for at least 2 weeks before enrolling in the study.
Disease severity was evaluated by the Psoriasis Area and
Severity Index (PASI) method [30]. The arthropathy was
assessed and periodically monitored through the count of
swollen and tender joints [34]. An age and sexmatched group
composed of 20 healthy subjects undergoing an institutional
health surveillance programwas used as a reference group for
the assessment of the levels of circulating lymphocyte subsets,
including regulatory T cells (Treg). All patients as well as
reference subjects signed a written informed consent.
2.3. Treatment. Patients were assigned to treatment arms
with either etanercept or adalimumab or infliximab, accord-
ing to the criteria indicated by international guidelines [35,
36]. Drugs were administered as follows: infliximab (5mg/kg
administered intravenously at 0, 2, and 6weeks and thereafter
every 8 weeks), etanercept (50mg subcutaneous twice weekly
for 12 weeks and then 25mg subcutaneous twice weekly),
and adalimumab (80mg subcutaneous at week 0 and then
40mg every other week). Subcutaneous injections were self-
administered by the patients. Clinical monitoring included
physical examination and instrumental as well as laboratory
diagnostic procedures (X-ray thorax, tuberculosis test, and
blood cell test). Disease severity was assessed before therapy
(T0) and after 12 (T1) and 24 (T2) weeks. The therapeutic
efficacy was defined as the achievement of a reduction of at
least 50% (PASI50), 75% (PASI75), or 90% (PASI90), respec-
tively, by PASI evaluation. Eight out of the 59 patients had
only arthritis andhave not been included in the analysis based
on PASI evaluation (Table 2). In arthropathic patients, the
improvement of joint involvement was evaluated by clinical
examination, by establishing and recording the number of
swollen joints.
2.4. Laboratory Immune Monitoring. Laboratory monitoring
was performed at baseline (T0), 12 weeks (T1), and 24 weeks
(T2), respectively.
2.4.1. Soluble Biomarkers. Serum samples were stored frozen
at −30∘C. Measurements of IL-1𝛼, IL-1𝛽, IL-2, IL-6, IL-10, IL-
12p70, IFN-𝛾, TNF-𝛼 were performed by a multiplex sand-
wich ELISA (Human Cytokine Array 1, Aushon Biosystem,
USA) and the SearchLight Plus Analysis System and Array
Analyst software (Aushon Biosystem), respectively, accord-
ing to the manufacturer instructions. Concentrations were
expressed as pg/mL. Assay sensitivity ranged between 0.2
and 0.4 pg/mL. Detection of IL-17 and IL-22 was performed
by ELISA (Platinum ELISA, e-Bioscience, BenderMedSys-
tem GmbH, Vienna, Austria). The sensitivity was 0.5 and
3.4 pg/mL, respectively.
2.4.2. Cellular Biomarkers. Whole blood EDTA (10mL) was
used to assess lymphocyte subsets by flow cytometry (FAC-
SCanto II flow cytometer, BDBiosciences). T, B,NK, andTreg
as well as CLA+ T lymphocytes were determined byMultitest
TBNK, CD45-PECy7, CD3-PerCyP, CLA-FITC (HECA-452)
(Pharmingen-BD Biosciences), and human Treg flow kit
(CD4-PECy-5, CD25-PE, FoxP3 Alexa Fluor, BioLegend, San
Diego, CA).
2.4.3. Functional Assays. Peripheral bloodmononuclear cells
(PBMC) were obtained by Ficoll gradient centrifugation
(UNI-SEP Tubes, Novamed Ltd, Israel). Proliferation assays
toward recall antigens were performed by flow cytometry
using 5- and 6-carboxyfluorescein diacetate succinimidyl
ester (CellTraceCFSECell Proliferation kit,Molecular probes
TM, Invitrogen) as described [37]. Briefly, PBMC were
washed in PBS w/o Ca++ and Mg++ and stained with
CFSE by 10min incubation at 37∘C with 0.4 𝜇M CFSE
in PBS supplemented with 0.1% fetal bovine serum (FBS,
GIBCO). Staining was stopped by adding 5 volumes of ice-
cold complete medium (RPMI with 10% FBS, GIBCO). After
washing twice with cold medium, cells were plated in a 96-
well microtiter plate at 0.3 × 106/0.2mL/well. Antigens were
tested in triplicate and included Candida albicans (5mg/mL)
andCEFpeptide pool, comprisingCytomegalovirus, Epstein-
Barr, and Flu viruses peptides (2𝜇g/mL) (NanogenAdvanced
Diagnostics).The superantigen Enterotoxin B from Staphylo-
coccus aureus (SEB, 0.25𝜇g/mL, SIGMA-Aldrich) was used
as positive control. Negative controls were constituted by
triplicate wells with cells plated in complete medium. After 6
days of incubation at 37∘C, 5% CO
2
, plates were centrifuged
for 4min at 1200 rpm, washed, and harvested.
Triplicate wells were pooled and stained with a mix of
anti-CD4-APC-Cy7, anti-CD8-PE-Cy7, and anti-CD25-APC
(BDBiosciences, San Jose, CA, USA). Cells were then washed
twice with BD CellWash and analyzed by flow cytometry.
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Figure 1: Individual levels (dots) and median values (line) of TNF-
𝛼, IFN-𝛾, IL-1𝛼, IL-1𝛽, IL-2, IL-6, IL-8, IL-10, IL-12p70, IL-17, and
IL-22 in sera collected at baseline (T0), before therapy initiation.
The results were analyzed by the ModFit software (Verity
Software House, Inc.) and expressed as Proliferation Index
(PI), after normalization for the number of acquired events,
subtracted from the value of the control sample, and as fold
increase (FI), calculated as the ratio of PI in the presence of
the specific antigens and the PI values of control samples.
Proliferative responses were considered positive when FI was
32.
2.5. Statistical Analysis. Statistical analysis was performed
using the Graph Pad Software Prism 4 (GraphPad Software
Inc., San Diego, CA). One way ANOVA (and related non-
parametric tests) for repeated measures was used to compare
baseline measurements with those obtained during treat-
ment. Comparisons between two groups were performed by
𝑡-test.The Graph Pad Software Prism test for deviations from
Gaussian distribution was performed using the Kolmogorov-
Smirnov test (normality test).
3. Results
3.1. Clinical Efficacy. Table 2 shows the response rate for
PASI50, PASI75, and PASI 90 after 12 and 24 weeks of treat-
ment in the all patients group and for each group of treatment.
The best clinical efficacy was achieved with infliximab and
adalimumab which showed the highest responder rates at
12 and 24 weeks. Etanercept effect was less pronounced at
earlier time points and became evident after a longer time of
observation.
3.2. Soluble Biomarkers. Themeasurement of TNF-𝛼, IFN-𝛾,
IL-1𝛼, IL-1𝛽, IL-2, IL-6, IL-8, IL-10, IL-12p70, IL-17, and IL-
22 in sera collected before therapy showed an increase in
the levels of IL-6, IL-8, and IL-22, as shown in Figure 1.
Consequently, these cytokines were assessed during the
therapeutic follow-up. The results, summarized in Figure 2,
showed a significant reduction of IL-6 and IL-22 induced
by therapy after 24 weeks of treatment in all patient groups,
while the levels of IL-8 were not significantly modified. The
reduction of IL-22 was found in all treatment groups, while
IL-6 reduction was statistically significant only when the
analysis was performed considering all patient groups.
3.3. Cellular Biomarkers. Determination of lymphocyte sub-
sets at baseline showed that patients with psoriasis had higher
CLA+ T cells and lower Treg lymphocytes, compared to
the reference subjects (Figure 3). The difference was highly
significant for CLA+ T cells: median values and ranges were
3.7% (0.9–8) in patients and 1.3% (0.5–2) in the reference
subjects, 𝑃 < 0.0001. A borderline significance was found
for Treg cells: median values and ranges were 1.55% (0.2–
5.4) in patients and 1.95% (1.1–3.2) in the reference group,
𝑃 = 0.08. However, Treg levels were significantly lower in
patients with joint involvement 1.14% (0.1–3.7) as compared
to patients without arthritis, 1.69% (0.4–5.4), 𝑃 = 0.04,
while no difference was observed considering CLA T cells:
1.4% (0.2−3.7) in patients with and 1.7% (0.4–5.4) in patients
without joint involvement, 𝑃 = 0.86. The analysis of T cell
subsets, B cells, andNK lymphocytes at baseline did not show
significant differences as compared to the reference subjects
(Figure 4). However, a slight increase of NK and B cells was
observed during therapy at 24weeks, particularly considering
the etanercept (Figure 5(a)) and adalimumab (Figure 5(b))
drug regimens, and was not seen under infliximab admin-
istration (Figure 5(c)). Interestingly, a significant decrease of
CLA+ T cells and a concomitant increase of Treg cells were
observed during 24 weeks of therapy (Figure 4), particularly
at 24 weeks (Figure 4). These effects were significantly asso-
ciated with the etanercept treatment (Figure 5(a)) and were
less evident under adalimumab (Figure 5(b)) or infliximab
(Figure 5(c)) therapeutic regimens.
3.4. Response to Recall Antigens. To assess the integrity of
the adaptive immune responses under drug regimens which
target key immune circuitries, proliferation assays toward
recall antigens were performed at baseline and after 24
weeks of treatment. The results showed that both CD4
and CD8 responses against Candida albicans as well as
Cytomegalovirus, Epstein-Bar, and Flu viruses were con-
served or even increased under therapy (Figure 6).
4. Discussion
Several studies indicate that biological treatments for pso-
riasis have a higher clinical efficacy in comparison with
conventional drugs [32]. Results gathered in the present
study showed that the inhibition of TNF-𝛼 led to a clinical
improvement (PASI50-90) in 87% of patients. Considering
each therapeutic regimen, we found that adalimumab and
infliximab induced the higher response rate (PASI90 in 90%
of patients) already at week 12, while clinical improvement
under etanercept regimen was less pronounced at 12 and 24
weeks. However, it induced amore significantmodification of
T cell subsets, as compared to the other two drugs.Thismight
be explained by the fact that, according to recent studies,
etanercept has been shown to induce early biochemical
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Figure 3: Comparison (unpaired, nonparametric 𝑡-test) of baseline values of peripheral blood CD3+CLA+ or CD4+/CD25+/FoxP3+ T cells
(Treg) in overall patients and a group of healthy subjects or in psoriatic patients with (w) or without (w/o) joint disease. Depicted values are
median and interquartile ranges.
and cellular effects, which precede the clinical improvement
[38, 39].
Many studies have pointed out the role of cytokines and
angiogenic factors along with the upregulation of theTh1 and
Th17 immune response and a downregulation of T regulatory
cells in the pathogenesis of the psoriatic lesions [22, 23,
40] suggesting the potential for their use as biomarkers of
clinical response to therapy [41]. The analysis of cytokine
levels in our patients at baseline showed increased levels of
IL-6, IL-8, and IL-22. These cytokines were thus monitored
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Figure 5: Continued.
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Figure 5: Analysis of lymphocyte subsets (T, B, NK lymphocytes, CD3+CLA+ and Treg cells) in peripheral blood of psoriasis patients before
and during therapy with etanercept (a), adalimumab (b), and infliximab (c). Measurements were compared by one way ANOVA for repeated
measures, nonparametric test. Depicted values are median and interquartile ranges.
during therapy. Increased IL-8 may represent a relevant sign
of disease activity, since it is produced by keratinocytes in
response to IL-1 or TNF-𝛼 [42] and, as a chemokine, has
relevant proinflammatory and angiogenic properties [43, 44].
However, serum levels of IL-8 did not decrease in concert
with the clinical improvement, in our patients. We rather
found a significant reduction of both IL-6 and IL-22 levels
during therapy. Our data thus confirm the involvement of
Th22 cells in psoriasis, as recently suggested by other authors
which also found increased serum levels of IL-22 in the
presence of anincrease of IL-6 and in the absence of IL-17
increments [45]. In fact, IL-6 and TNF-𝛼 promote priming
of Th22 [46]. IL-22 is a member of the IL-10 cytokine family,
described as having proinflammatory activities on liver,
pancreas, intestine, and skin [47]. IL-22 production is upreg-
ulated in psoriatic lesion, due to infiltrating T effector cells,
which are a major source of IL-22 [27, 28]. Binding of IL-22
to its receptor leads to the activation of the Janus kinase and
the signal transducer and activator of transcription STAT3
and of the mitogen-activating peptide kinase pathways [48].
Of note, keratinocytes express high levels of IL-22 receptors
and are highly responsive to IL-22 [26]. On the other hand,
elevated levels of IL-6 have been reported in psoriasis either
in serum or in lesions [7, 40]. IL-6 pleiotropic effects include
stimulation of epidermal keratinocyte hyperplasia as well
as promotion of the differentiation of IL-17-producing T
lymphocytes and inhibition of Treg differentiation [49, 50].
Thus, the significant decrease of IL-6 and IL-22 levels in
associationwith the clinical improvement of patients suggests
that an at least partial restoration of an effective immune
regulation has been induced by the therapeutic regimens.
Indeed, the analyses of regulatory and effectorT lymphocytes,
that is, T cells expressing CLA as a skin homing receptor,
provide some support to this hypothesis. In fact, expression
of CLA plays an important role in the homing of memory
T cells to the skin, which, in turn, is essential for long-term
immune surveillance and themaintenance of barrier integrity
[13]. Over 80% of T cells infiltrating the skin express CLA
when compared to less than 20% and 5% in the peripheral
blood or in tissues other than skin, respectively [16]. CLA+ T
cells increase in evolving psoriatic lesions, as compared with
stable lesions as well as uninvolved skin.This accumulation of
CLA+ cells precedes epidermal hyperproliferation suggesting
that these cells may play a key role in the pathogenesis of
psoriasis [15] since in psoriasis CLA+T cells include self-
antigen-reactive T cells and IL-17 producing cells [51, 52].
In psoriasis, circulating CLA+ T cells correlate with disease
severity and a reduction in CLA expressing cells has been
reported in association with a clinical improvement after
methotrexate treatment [16]. In the present study, we found a
significant reduction of circulating CLA+ T cells after 12 and
24 weeks of therapy, particularly under etanercept regimen,
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Figure 6: Lymphocyte proliferation toward Candida albicans and
CEF antigens as performed at baseline (T0) and after 24 weeks
of treatment (T2) in a representative group of 30 patients under
therapy with etanercept (10), adalimumab (10), or infliximab (10).
Stimulation indexes of CD4+ (a) and CD8+ (b) lymphocytes.
which is administrated through intradermal injections. The
reduction of CLA+ peripheral T cells may reflect a reduction
in keratinocyte activation, since etanercept’s earliest target
appears to be epidermal keratinocytes [39]. On the other
hand, regulatory T cells play a crucial role in the processes
of peripheral tolerance and are pivotal for controlling the
outgrowth of potentially pathogenic self-reactive T cells
[28]. Lower levels of Treg cells in both skin and peripheral
blood have been shown in progressive disease while higher
levels were found in stable or regressive lesions [53, 54].
In the present study, Treg levels at baseline were lower,
though not significantly, than those found in the reference
group. However, patients with PsA had the lowest number
of Treg cells at baseline, significantly below the levels found
in patients without PsA as well as in the reference group.
Remarkably, after 24 weeks of therapy, Treg were increased
in peripheral blood, in association with the other parameters
of clinical efficacy. Most pronounced results were obtained
upon etanercept administration. Previous studies have shown
that anti-TNF-𝛼-based treatment induces an increase of
Treg lymphocytes in patients with psoriasis [55]. Indeed, a
recent study has shown that TNF-𝛼 inhibits the suppressive
function of Treg cells in vitro [17]. Thus, according to this
notion, the increments of Treg cells under anti-TNF-𝛼-
based treatment may represent a key factor in restoring
a more appropriate regulation of the adaptive immune
response with an effective suppression of CLA+ autoreactive
T cells.
The assessment of immunological safety, that is, the
preservation of the integrity of immune functions, was
performed by assessing peripheral lymphocyte subsets as
well as the response to recall antigens. T, B, and NK cell
counts at baseline did not significantly differ from those of
an age and sex matched reference group. The administration
of anti-TNF-𝛼-based therapy did not alter either CD4 or CD8
numbers. Conversely, a slight increase in B and NK cells was
observed, though with some differences among the different
drugs. In particular, etanercept induced mainly increases of
NK cells while Humira induced mainly B cell increments.
The increment of NK cells, which are key components
of the innate immune defense system [55], is intriguing,
since NK cells have been shown to exert also regulatory
functions on antigen-specificT andB cell responses, although
their role in psoriasis has been poorly explored, as yet
[56, 57].
Regarding the potential influence of anti-TNF-𝛼-based
therapy on the setting of adaptive immune functional
responses against viral and bacterial antigens, previous
reports in different inflammatory diseases, including pso-
riasis and psoriatic arthritis, rheumatoid arthritis, spondy-
loarthritis, and Crohn’s disease, showed that most common
adverse events are represented by the occurrence of infections
and by an unexpected high frequency of reactivation of latent
tuberculosis infections (LTB), which are often severe and
characterized by extrapulmonary and disseminated lesions
[58].
Our data, however, suggest that functional immune
responses against different recall antigens are remarkably
preserved and possibly even increased during a 24-week
follow-up of anti-TNF-𝛼 administration.
5. Conclusions
Theclinical efficacy of anti-TNF-𝛼 drugs in patients with pso-
riasis and/or joint disease was associated with (i) reduction of
IL-6 and IL-22 in sera; (ii) increments of regulatory T cells;
(iii) reduction of cutaneous homing receptor expressing T
cells. This finding indicates that these laboratory parameters
may represent useful surrogate biomarkers for the clinical
monitoring and therapeutic management of psoriasis.
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